Abstract:
Aim: To determine and compare hepatotoxic effects caused by escitalopram versus sertraline in patients with major depressive disorder. Study Design: Comparative longitudinal study Place and Duration of Study: Department of Pharmacology, Basic Medical Sciences Institute (BMSI) & Neuropsychiatry Ward of Jinnah Postgraduate Medical Centre (JPMC) Karachi from January 2017 to December 2017. Methods: One hundred and twenty eight patients divided into four groups; group 1 (recent users for a period of >1 month to =3 months), group 2 (drug users for a period of >6 months to =9 months), group 3 (drug users for a period of >1 year to =2 years and group 4 (drug users for a period of >2years to =5 years.) and each group consists of 32 patients. Out of these 32 patients, 16 patients were escitalopram users (10-20mg) and 16 patients were sertraline users (50mg). Out of these 16 patients, 8 patients were males and 8 patients were females. Results:The mean comparison of LFT parameters between two treatment groups results showed in escitalopram samples, mean±SD for Bilirubin was 0.91±0.38, SGPT 61.24±12.0, alkaline phosphatase 213.63±53.03, whereas in treatment group sertraline, mean±SD of bilirubin was 0.69±0.16, SGPT 36.88±9.34, alkaline phosphatase 221.69±108.9, there was significant mean difference observed for bilirubin and SGPT between two treatment groups with p-value less than 0.01. Conclusion:Both escitalopram and sertraline can cause hepatotoxicity.
Page(s):
458-461
DOI:
DOI not available
Published:
Journal: Pakistan Journal of Medical and Health Sciences, Volume: 14, Issue: 2, Year: 2020
Keywords:
Major depressive disorder MDD
,
Selective serotonin reuptake inhibitors SSRIs
,
Liver function test LFT